Payment overview · 2025
General Payments
$352.28
20 reported records · 11 companies
Healthcare provider profile · identity verified
Drew A Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WARSAW, MO · NPI 1083682991
Verified facts
What the public records show
CMS Open Payments records show Drew A Smith, M.D. received $352.28 in general payments during 2025 across 20 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Jardiance by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xeljanz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $75.24 | 21.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.64 | 17.8% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.62 | 14.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.71 | 9.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.79 | 7.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.90 | 6.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.34 | 5.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.86 | 4.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.70 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.62 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.86 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $352.28 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $75.24 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $62.64 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $52.62 | 3 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
325 | 57 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 628 | 164 |
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 600 | 140 |
| Lisinopril | Lisinopril | 593 | 150 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 556 | 97 |
| Omeprazole | Omeprazole | 514 | 114 |
| Gabapentin | Gabapentin | 449 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 95 |
| Losartan Potassium | Losartan Potassium | 362 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 346 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 337 | 74 |
| Tramadol Hcl | Tramadol Hcl | 330 | 62 |
| Jardiance | Empagliflozin | 325 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 69 |
| Sertraline Hcl | Sertraline Hcl | 301 | 53 |
| Alprazolam | Alprazolam | 298 | 54 |
| Metformin Hcl | Metformin Hcl | 296 | 70 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 278 | 35 |
| Ozempic | Semaglutide | 220 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 207 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 54 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 197 | 49 |
| Carvedilol | Carvedilol | 195 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 195 | 49 |
| Montelukast Sodium | Montelukast Sodium | 194 | 40 |
| Pregabalin | Pregabalin | 192 | 32 |
| Furosemide | Furosemide | 182 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 26 |
| Buspirone Hcl | Buspirone Hcl | 171 | 29 |
| Potassium Chloride | Potassium Chloride | 171 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 31 |
| Eliquis | Apixaban | 151 | 22 |
| Simvastatin | Simvastatin | 149 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 145 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 48 |
| Trazodone Hcl | Trazodone Hcl | 136 | 31 |
| Glimepiride | Glimepiride | 135 | 30 |
| Warfarin Sodium | Warfarin Sodium | 133 | 17 |
| Allopurinol | Allopurinol | 129 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 34 |
| Celecoxib | Celecoxib | 128 | 32 |
| Meloxicam | Meloxicam | 126 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 30 |
| Famotidine | Famotidine | 112 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 34 |
| Lovastatin | Lovastatin | 111 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 19 |
| Finasteride | Finasteride | 104 | 21 |
| Xarelto | Rivaroxaban | 97 | 16 |
| Donepezil Hcl | Donepezil Hcl | 96 | 20 |
| Baclofen | Baclofen | 94 | 24 |
| Alendronate Sodium | Alendronate Sodium | 90 | 23 |
| Metformin Hcl Er | Metformin Hcl | 89 | 17 |
| Prednisone | Prednisone | 89 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 21 |
| Clonazepam | Clonazepam | 77 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 18 |
| Azelastine Hcl | Azelastine Hcl | 70 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 18 |
| Spironolactone | Spironolactone | 69 | 18 |
| Torsemide | Torsemide | 69 | 21 |
| Fentanyl | Fentanyl | 66 | suppressed |
| Bupropion Xl | Bupropion Hcl | 62 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 61 | 15 |
| Lorazepam | Lorazepam | 59 | 17 |
| Aripiprazole | Aripiprazole | 58 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 26 |
| Temazepam | Temazepam | 54 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Xtampza Er | Oxycodone Myristate | 53 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 50 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 42 |
| Cephalexin | Cephalexin | 45 | 33 |
| Chlorthalidone | Chlorthalidone | 45 | 11 |
| Diazepam | Diazepam | 44 | 13 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 43 | 11 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 22 |
| Primidone | Primidone | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Nitroglycerin | Nitroglycerin | 38 | 23 |
| Bumetanide | Bumetanide | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 13 |
| Estradiol | Estradiol | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 12 |
| Fluconazole | Fluconazole | 31 | 18 |
| Invokana | Canagliflozin | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Carisoprodol | Carisoprodol | 29 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 25 |
| Novolog Flexpen | Insulin Aspart | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Colchicine | Colchicine | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Verapamil Sr | Verapamil Hcl | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 17 |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Xeljanz | Tofacitinib Citrate | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $352.28 · 20 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, GARDASIL 9, LEQVIO, M-M-R II, NURTEC ODT, REXULTI, VAXELIS, VAXNEUVANCE, VRAYLAR, Veozah, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error